Search Results - "Körfer, A."

Home therapy with recombinant interleukin-2 and interferon-alpha 2b in advanced human malignancies by Atzpodien, J, Körfer, A, Franks, C R, Poliwoda, H, Kirchner, H

“…The safety, tolerance, and clinical effects of a home therapy regimen of recombinant human interleukin-2 (rIL-2) and interferon-alpha 2b (IFN-alpha 2b) self…”
Get more information

Chemoimmunotherapy of advanced malignant melanoma: sequential administration of subcutaneous interleukin-2 and interferon-α after intravenous dacarbazine and carboplatin or intravenous dacarbazine, cisplatin, carmustine and tamoxifen by Atzpodien, J., Lopez Hänninen, E., Kirchner, H., Franzke, A., Körfer, A., Volkenandt, M., Duensing, S., Schomburg, A., Chaitchik, S., Poliwoda, H.

“…Both chemotherapy and interleukin-2 and/or interferon-α produce objective responses in a proportion of advanced malignant melanoma patients. While duration of…”
Get full text

Low-dose subcutaneous recombinant interleukin-2 in advanced human malignancy: a phase II outpatient study by Atzpodien, J, Körfer, A, Evers, P, Franks, C R, Knüver-Hopf, J, Lopez-Hänninen, E, Fischer, M, Mohr, H, Dallmann, I, Hadam, M

“…Recombinant interleukin-2 (rIL-2; EuroCetus, Amsterdam, Netherlands) was studied in an outpatient phase II trial in 14 patients with progressive metastatic…”
Get more information

Subcutaneous interleukin-2 and interferon-alpha 2b in patients with metastatic renal cell cancer: the German outpatient experience by Kirchner, H, Körfer, A, Palmer, P A, Evers, P, De Riese, W, Knüver-Hopf, J, Hadam, M, Goldman, U, Franks, C R, Poliwoda, H

“…A phase II clinical trial was conducted using subcutaneous recombinant human interleukin-2 (rIL-2, EuroCetus) and subcutaneous interferon-alpha 2b (rIFN-alpha…”
Get more information

Diminished expression of interleukin-2 receptors in vivo after prior chemotherapy in advanced cancer patients receiving recombinant interleukin-2 by Atzpodien, J, Körfer, A, Hadam, M, Schomburg, A, Menzel, T, Dallmann, I, Poliwoda, H, Kirchner, H

“…In a phase I/II dose escalation study performed at our institution, a total of 14 advanced metastatic cancer patients received between 4 and 16 weeks of…”
Get more information

European studies of interleukin-2 in metastatic renal cell carcinoma by Atzpodien, J, Kirchner, H, Hänninen, E L, Körfer, A, Fenner, M, Menzel, T, Deckert, M, Franzke, A, Jonas, U, Poliwoda, H

Get more information

Biological monitoring of low-dose interleukin 2 in humans : soluble interleukin 2 receptors, cytokines, and cell surface phenotypes by LOPEZ HANNINEN, E, KORFER, A, HADAM, M, SCHNEEKLOTH, C, DALLMANN, I, MENZEL, T, KIRCHNER, H, POLIWODA, H, ATZPODIEN, J

“…Different immunotherapy regimens using s.c. recombinant interleukin-2 (rIL-2) were studied in 76 patients with progressive metastatic renal carcinoma,…”
Get full text

Treatment of metastatic renal cell cancer patients with recombinant subcutaneous human interleukin-2 and interferon-alpha by Atzpodien, J, Körfer, A, Palmer, P A, Franks, C R, Poliwoda, H, Kirchner, H

“…We treated 17 patients who had progressive metastatic renal carcinoma with a combination of subcutaneous recombinant human interleukin-2 (administered every 12…”
Get more information

Hepatic and serologic toxicity of systemic interleukin-2 and/or interferon-alpha. Evidence of a risk-benefit advantage of subcutaneous therapy by Schomburg, A, Kirchner, H, Lopez-Hänninen, E, Menzel, T, Rudolph, P, Körfer, A, Fenner, M, Poliwoda, H, Atzpodien, J

“…A total of 107 cancer patients were treated with 148 cycles of subcutaneous (SC) immunotherapy employing interleukin-2 (rIL-2) and/or interferon-alpha…”
Get more information

The development of neutralizing antibodies in a patient receiving subcutaneous recombinant and natural interleukin-2 by Kirchner, H, Körfer, A, Evers, P, Szamel, M M, Knüver-Hopf, J, Mohr, H, Franks, C R, Pohl, U, Resch, K, Hadam, M

“…Systemic administration of interleukin-2 (IL-2) in humans may induce antibodies specific to IL-2. The case is reported of a patient with metastatic rectal…”
Get more information

Expansion of peripheral blood natural killer cells correlates with clinical outcome in cancer patients receiving recombinant subcutaneous interleukin-2 and interferon-alpha-2 by Atzpodien, J, Kirchner, H, Körfer, A, Hadam, M, Schomburg, A, Menzel, T, Deckert, M, Franzke, A, Volkenandt, M, Dallmann, I

“…Natural killer (NK) cells are believed to contribute to the clinical efficacy of cancer immunotherapy using recombinant interleukin-2 (rIL-2) in humans. In…”
Get more information

Biologic and therapeutic efficacy of mafosfamide in patients with metastatic renal cell carcinoma by Schomburg, A, Menzel, T, Hadam, M, Duensing, S, Körfer, A, Kirchner, H, Poliwoda, H, Atzpodien, J

“…It is well known that oxazaphosphorines [e.g., cyclophosphamide and 4-hydroperoxycyclophosphamide (mafosfamide)] are potent immunosuppressive agents. Under the…”
Get more information

Pretreatment natural killer antigen density correlates to clinical response in tumor patients receiving long-term subcutaneous recombinant interleukin-2 and recombinant interferon-alpha by Duensing, S, Hadam, M, Körfer, A, Schomburg, A, Menzel, T, Grosse, J, Kirchner, H, Poliwoda, H, Atzpodien, J

“…We evaluated density of the natural killer (NK) cell-associated CD56 antigen on circulating NK cells of 47 patients with advanced renal cell carcinoma…”
Get more information

Five-day 4'-(9-acridinylamino)methanesulphon-m-anisidide and intermediate-dose cytosine arabinoside in high-risk relapsing or refractory acute myeloid leukemia by FREUND, M, GILLER, S, HINRICHS, F, BAARS, A, MERAN, J, KORFER, A, LINK, H, POLIWODA, H

“…Twenty-two patients with acute myeloid leukemia (AML), having a median age of 48.3 years (range 26-70; 10 male, 12 female), were treated with…”
Get full text

In vivo and ex vivo antitumor activity in patients receiving low-dose subcutaneous recombinant interleukin-2 by Schomburg, A, Menzel, T, Körfer, A, Heer, G, Dallmann, I, Kirchner, H, Poliwoda, H, Atzpodien, J

“…Alterations in cell-mediated cytotoxicity levels were studied in patients receiving recombinant interleukin-2 (rIL-2) via subcutaneous injection. Fourteen…”
Get more information

Clinical and preclinical evaluation of recombinant PEG-IL-2 in human by Menzel, T, Schomburg, A, Körfer, A, Hadam, M, Meffert, M, Dallmann, I, Casper, S, Kirchner, H, Poliwoda, H, Atzpodien, J

“…High dose interleukin-2 alone or in combination with lymphokine activated killer (LAK) cells has demonstrated antitumor activity in a variety of malignant…”
Get more information

Low-dose interleukin-2 in combination with interferon-alpha effectively modulates biological response in vivo by Schneekloth, C, Körfer, A, Hadam, M, Lopez Hänninen, E, Menzel, T, Schomburg, A, Dallmann, I, Kirchner, H, Poliwoda, H, Atzpodien, J

“…Phenotypic characterization of peripheral blood lymphocytes was performed in patients with advanced metastatic cancer receiving low-dose recombinant…”
Get more information

Network and integrated coastal zone management: a look of geographers by Morel, V, Korfer, A, Deboudt, P

“…Studying social networks related to Integrated Coastal Zone Management (ICZM) in Europe is a new way to approach ICZM from a different angle. Theoretically,…”
Get full text

Immunophenotypic demonstration of two natural killer surface markers, H25 and H366, on fresh human leukemic cells by Körfer, A, Kirchner, H, Schneekloth, C, Bührer, C, Wisniewski, D, Gulati, S, Clarkson, B, Knowles, R, Poliwoda, H, Atzpodien, J

“…Using a modified alkaline-phosphatase/antialkaline-phosphatase method for phenotyping fresh human leukemias, we could demonstrate peripheral blood and bone…”
Get more information